News
We send the latest information from SMC Laboratories.
New Service: In Vitro Assay for Fibrosis Evaluation
We are delighted to announce the launch of our new in vitro assay service for fibrosis evaluation.  …
Introducing our new pulmonary fibrosis model: Silica-induced pulmonary fibrosis model
Today, we are pleased to announce that we have expanded our preclinical model lineup by including the “S…
Study published in Pharmacol Res Perspect. on the efficacy of the inhibitor of serine palmitoyltransferase (SPT) in STAM™
SMC is proud to announce that Chugai Pharmaceutical Co., Ltd. (JPN) has published the results of their study u…
Introduction of Inflammatory Bowel Disease mouse model
Today, we give you a brief introduction to the dextran sulfate sodium (DSS) -induced colitis model, which is a…
Study published in Int. J. Mol. Sci. on the efficacy of Mesenchymal stromal cell/stem cell small extracellular vesicles (MSC-sEV) in STAM™
SMC is proud to announce that Agency for Science, Technology and Research (A*STAR) (SGP) has published the res…
Announcement of webinar 【HOW NAFLD ACTIVITY SCORE IS SCORED IN NON-CLINICAL STUDIES】
Today we are excited to invite you to join our Online Linkedin Webinar that will be taking place on May 18th (…
The STAM™ mouse model: a clinically relevant, spontaneous HCC model
We would like to introduce a study published by our client using our STAM™ mouse model (Dow, et al. Proc…
Introduction of chronic kidney disease mice models
I am writing you today to share some information on our Chronic kidney disease (CKD) models. CKD is a c…
SMC attend Digital partnering events!
We are pleased to announce that SMC Laboratories will be virtually attending the following digital events in M…
Introduction of NASH model with high clinical correlation
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide. Around t…